- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Thyrotoxicosis.
Displaying page 1 of 1.
EudraCT Number: 2021-001941-11 | Sponsor Protocol Number: 2021-1798 | Start Date*: 2021-09-09 | ||||||||||||||||
Sponsor Name:Rijnstate hospital | ||||||||||||||||||
Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules. | ||||||||||||||||||
Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000832-26 | Sponsor Protocol Number: 2005 02 03 | Start Date*: 2006-01-25 |
Sponsor Name:Department of Endocrinology | ||
Full Title: Adjuvant treatment of Graves´ ophthalmopathy with NSAID (aGO study) | ||
Medical condition: Graves´ophthalmopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002280-14 | Sponsor Protocol Number: L00006 CP 403 3A | Start Date*: 2008-07-18 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ... | |||||||||||||
Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002894-27 | Sponsor Protocol Number: IMVT-1401-2501 | Start Date*: 2023-04-03 | |||||||||||
Sponsor Name:Immunovant Sciences GmbH | |||||||||||||
Full Title: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD) | |||||||||||||
Medical condition: Graves` disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004887-24 | Sponsor Protocol Number: NBK182/1/2020 | Start Date*: 2021-04-14 | |||||||||||
Sponsor Name:Marcin Gruchała Medical University of Gdańsk | |||||||||||||
Full Title: Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) | |||||||||||||
Medical condition: Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018289-21 | Sponsor Protocol Number: EndoIGA2010 | Start Date*: 2010-02-25 | |||||||||||||||||||||||||||||||
Sponsor Name:Insitute of Endocrinology | |||||||||||||||||||||||||||||||||
Full Title: Clinical, laboratory and ultrasound markers for the prediction of the response on the pulse-dose treatment by intravenous glucocorticoids in patients with endocrine orbitopathy | |||||||||||||||||||||||||||||||||
Medical condition: active severe endocrine orbitopathy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002147-91 | Sponsor Protocol Number: CV185-030 | Start Date*: 2007-05-14 | ||||||||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalv... | ||||||||||||||||||
Medical condition: ARRHYTHMIA; THROMBOSIS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NO (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
